ACC 2023: Late-Breaking Science Video Collection
Published: 06 March 2023
5m 34sPart 4 | Session 2 Lipid Management & the CLEAR Trial with Dr Erin Michos
Part 4 | Session 3 Obesity Management Strategies in 2023 with Dr Harold Bays
15m 9sPart 4 | Session 4 ACC.23 President Interview with Dr B Hadley Wilson
16:12Part 1 | Session 1 The CLEAR-Outcomes Trial with Dr Harriette Van Spall & Dr Steven Nissen Harriette Van Spall, Steven E Nissen
16:24Part 1 | Session 2 The REVIVED-BCIS2 Viability Study with Dr Harriette Van Spall, Dr Divaka Perera & Dr Peter O'Kane Harriette Van Spall, Divaka Perera, Peter O’Kane
Part 1 | Session 3 The BETTER-CARE HF Trial with Dr Harriette Van Spall & Dr Amrita Mukhopadhyay Amrita Mukhopadhyay, Harriette Van Spall
17m 32sPart 1 | Session 4 The COORDINATE-Diabetes Trial with Dr Harriette Van Spall, Dr Neha J Pagidipati & Dr Christopher B Granger Christopher B Granger, Harriette Van Spall, Neha Pagidipati
12m 7sPart 1 | Session 5 The BIOVASC Trial with Dr Harriette Van Spall & Prof Roberto Diletti Roberto Diletti, Harriette Van Spall
05:59Part 2 | Session 1 Statins to Protect Heart During Cancer Treatment: The STOP-CA Trial Marielle Scherrer-Crosbie
5m 38sPart 2 | Session 2 RENOVATE-COMPLEX-PCI: IVUS Vs OCT Optimisation in Complex PCI Joo-Yong Hahn
8m 1sPart 2 | Session 3 Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study Annapoorna Kini
5m 41sPart 2 | Session 4 Mini-Thoracotomy Vs Sternoctomy for Degenerative Valve Disease: The UK Mini-Mitral Study Enoch Akowuah
3m 46sPart 2 | Session 5 TAVR in Low-Risk Aortic Stenosis Patients: 3-Year Results From the Evolut Low Risk Trial John Forrest
5m 53sPart 2 | Session 6 Pulsed Field Ablation in Persistent Atrial Fibrillation Patients: The PULSED AF Trial Atul Verma
3m 44sPart 2 | Session 7 MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients Christie Ballantyne
5m 20sPart 2 | Session 8 Evaluation of the Mechanism of Benefit for Dapagliflozin in HFpEF Barry Borlaug
3m 7sPart 2 | Session 9 BMAD Trial: μCor in Ambulatory Decompensated Heart Failure John Boehmer
Part 2 | Session 10 The STELLAR Phase II Trial: Sotatercept in Patients With Pulmonary Arterial Hypertension Marius Hoeper
33m 28sPart 3 | Session 1 ACC.23 Late-breaking Science Wrap Up Nicolas M Van Mieghem, Joost Daemen
Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data.
For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviews the principal investigators in her regular Late-Breaker Discussion Series.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
More from this programme
Late-Breaker Discussion Series
Host, Dr Harriette Van Spall is joined by principle investigators for discussion on selected late-breaking trials.
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC 2023.
About the episode
Prof Nicolas Van Mieghem and Dr Joost Daemen return with their critical review series, View from the Thoraxcenter, to preview the most anticipated late-breaking and featured science trials of ACC.23.
Which trials have the potential to change practice? What are the key considerations for patient care and research? What is the context of the top trials of ACC?
Trials covered in detail include:
9:22: REVIVED-BCIS2: Effect of Myocardial Viability, Percutaneous Coronary Intervention and Functional Recovery on Clinical Outcomes
11:28: RENOVATE-COMPLEX-PCI: Intravascular Imaging-guided Versus Angiography-guided Procedural Optimization in Complex Percutaneous Coronary Intervention
14:19: BIOVASC: Complete Revascularization Strategies in Patients Presenting with Acute Coronary Syndromes and Multivessel Coronary Disease
15:55: Yellow III: Effect Of Evolocumab On Coronary Plaque Characteristics in Stable Coronary Artery Disease: A Multimodality Imaging Study
18:03: CLEAR Outcomes: Bempedoic Acid and Cardiovascular Outcomes in Statin Intolerant Patients At High Cardiovascular Risk
20:41: MK-0616: Efficacy And Safety of The Oral PCSK9 Inhibitor, MK-0616, A Macrocyclic Peptide, in the Treatment Of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial
Don't miss out on the latest developments in cardiology research!
Nicolas M Van Mieghem
Prof Nicolas Maria Van Mieghem is an Interventional cardiologist at Thoraxcenter, Erasmus MC, Rotterdam, NL decided to pursue a career that would help others. “I enjoy the feeling of being able to help someone or do something important for them". His father was a general cardiologist and one of his biggest influences early in his career.
Prof Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002. Prof Van Mieghem believes that great cardiologist genuinely cares for their patients. He names Gary Roubin, Dr Manu Malbrain and Professor Patrick Serruys among his mentors.
His current research focuses on cerebral embolic protection during TAVI and the search for improved…
Dr Joost Daemen, MD, PhD obtained his degree in medicine at the Erasmus University Medical Center, Rotterdam in 2005 and did 2 years of internal medicine training and 4 years of general cardiology training at the Thoraxcenter, Rotterdam.
Joost is actively involved in several drug-eluting stent trials and is Principal Investigator of 4 trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Joost is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.